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The mRNA targets of microRNAs (miRNAs) can be
identified by immunoprecipitation of Argonaute (Ago)
protein-containing RNA-induced silencing com-
plexes (RISCs) followed by microarray analysis
(RIP-Chip). Here we used Ago2-based RIP-Chip to
identify transcripts targeted by Kaposi’s sarcoma-
associated herpesvirus (KSHV) miRNAs (n = 114),
Epstein-Barr virus (EBV) miRNAs (n = 44), and cellular
miRNAs (n = 2337) in six latently infected or stably
transduced human B cell lines. Of the six KSHV
miRNA targets chosen for validation, four showed
regulation via their 30UTR, while two showed regula-
tion via binding sites within coding sequences.
Two genes governing cellular transport processes
(TOMM22 and IPO7) were confirmed to be targeted
by EBV miRNAs. A significant number of viral miRNA
targets were upregulated in infected cells, suggest-
ing that viral miRNAs preferentially target cellular
genes induced upon infection. Transcript half-life
both of cellular and viral miRNA targets negatively
correlated with recruitment to RISC complexes, indi-
cating that RIP-Chip offers a quantitative estimate of
miRNA function.
INTRODUCTION
Herpesviruses are large DNA viruses which after primary infec-
tion persist for life, leaving the infected individual at risk for reac-
tivation and subsequent disease. They are divided into three
subfamilies based on sequence homologies and unique biolog-
ical features (a-, b-, and g-herpesviruses). Humans are infected324 Cell Host & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier Inwith two members of the g-herpesvirus family, namely Kaposi’s
sarcoma-associated herpesvirus (KSHV) and Epstein-Barr
virus (EBV). Both infect B cells and can induce proliferative
diseases in humans (Barozzi et al., 2007). KSHV is involved in
the development of several human tumors, including Kaposi’s
sarcoma, primary effusion lymphoma (PEL), and multicentric
Castleman disease (reviewed in Dourmishev et al., 2003;
Schulz, 2006). PEL tumor cells are thought to originate from
postgerminal center B cells due to the presence of hypermutated
immunoglobulin genes (Gaidano et al., 1997) and display an
intermediate immunophenotype between immunoblasts and
plasma cells (Carbone et al., 1996; Nador et al., 1996). The cell
line body cavity-based lymphoma-1 (BCBL-1) was established
from a malignant effusion (Renne et al., 1996) and serves as
a model cell line for PEL. Four groups independently reported
on 12 miRNAs expressed during latent infection in PEL cells
(Cai et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005;
Samols et al., 2005), which are remarkably conserved among
isolates from many different clinical sources (Marshall et al.,
2007).
EBV has been linked to various human malignancies including
Burkitt’s and Hodgkin’s lymphoma, NK/T cell and peripheral
T cell lymphoma, posttransplant lymphoma, and nasopharyn-
geal and gastric carcinoma and is responsible for posttransplant
lymphoproliferative disease (PTLD) (Delecluse et al., 2007). EBV
readily transforms primary human B-lymphocytes which are the
in vitro correlate of EBV-associated PTLD arising under severe
immunosuppression (Carbone et al., 2008). EBV encodes for at
least 25 miRNAs derived from three separate miRNA clusters
(Cai et al., 2006; Grundhoff et al., 2006; Pfeffer et al., 2004;
Zhu et al., 2009).
Since viral miRNAs were first described in 2004 (Pfeffer et al.,
2004), only very few targets have been identified. For KSHV
these include targets involved in angiogenesis, proliferation,
immune evasion, or repression of apoptosis (Gottwein et al.,
2007; Nachmani et al., 2009; Samols et al., 2007; Skalskyc.
Figure 1. Overrepresentation of Predicted Binding Sites for Cellular
miRNAs
Binding sites for these 44 cellular miRNAs expressed in human B cells (Land-
graf et al., 2007) were predicted using PITA software and different cutoffs for
free binding energies (DDG) ranging from 0 to 10 kcal/mol. Odds ratios for
predicted miRNA-binding sites are shown for all genes with a mean enrich-
ment in the Ago2-IP versus control across all six cell lines greater than the indi-
cated value. For each value, the number of transcripts with a mean enrichment
greater than this cutoff is shown.
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promote cell survival (Choy et al., 2008) and target cellular
chemokines (CXCL-11) (Xia et al., 2008). Similar to human cyto-
megalovirus miR-UL112-1, both kshv-miR-K12-7 and ebv-miR-
BART2 target MICB, an activating stress-induced NK cell ligand
involved in immune recognition of infected cells (Nachmani et al.,
2009; Stern-Ginossar et al., 2007).
Recently, immunoprecipitation of RISCs followed by microar-
ray analysis of the RISC-bound miRNA targets (RIP-Chip) was
shown to permit the identification of hundreds of cellular miRNA
targets with high specificity (Baroni et al., 2008; Beitzinger et al.,
2007; Easow et al., 2007; Hendrickson et al., 2008; Karginov
et al., 2007; Keene et al., 2006). Here we applied Argonaute 2
(Ago2)-RIP-Chip to identify both cellular and viral miRNA targets
in six human B cell lines. We report on the identification of 2337
putative targets of cellular and 158 targets of viral miRNAs in
human B cells. Thus, we provide a comprehensive atlas of
cellular miRNA targets in human B cells and extend the list of
cellular targets of all viral miRNA targets identified so far by
> 5-fold.
RESULTS
Study Design
Cellular targets of human g-herpesvirus miRNAs in B cells were
identified by immunoprecipitation (IP) of RISCs followed by
microarray analysis of the coimmunoprecipitated mRNAs (RIP-
Chip). To identify KSHV miRNA targets, we used the KSHV-posi-
tive cell line BCBL-1 and the KSHV- and EBV-negative cell line
DG75 transduced by a lentiviral vector to stably express the
ten intronic KSHV miRNAs (DG75-10/12). DG75 transduced
with eGFP (DG75-eGFP) served as control (Wang et al., 2004).
To identify viral miRNA targets of EBV, the prototype B95.8 strain
of EBV (BL41 B95.8) and its parental Burkitt’s lymphoma cell line
(BL41) were used. As B95.8 has lost more than half of the viral
miRNAs (Cai et al., 2006), the Jijoye cell line featuring a nonde-
leted strain, where all known EBV miRNAs are present (Grundh-
off et al., 2006), was included.
Identification of Cellular miRNA Targets
in Human B Cells
We established a protocol for RISC IP in human B cells using
the recently described monoclonal antibody to human Ago2
(a-hAgo2; 11A9) (Rudel et al., 2008). A monoclonal antibody
against bromodesoxyuridine (BrdU) served as control. In all
experiments the efficiency of the IP was analyzed by quantitative
PCR. Usually, an 1000-fold (670- to 3300-fold) enrichment of
cellular Let7a levels was observed when comparing the Ago2-IP
with the BrdU-IP samples. A consistent recovery rate of50% of
Let7a was observed, indicating that Ago2-bound miRNAs
comprise at least half of the cellular miRNA pool in human B cells
(see Figure S1 available online). Enrichment of cyclin E1 mRNA
(CCNE1), a cellular miRNA target of both hsa-miR-16 and hsa-
miR-15a (Bandi et al., 2009; Liu et al., 2008), served as a positive
control. It was typically enriched by 8-fold.
Next, microarray analyses of two independent biological
replicates for each cell line were performed using Affymetrix
human Gene ST 1.0 arrays. For DG75-eGFP, DG75-10/12, and
BCBL-1, both the a-Ago2-IP and the a-BrdU-IP samples wereCellanalyzed. For both BL41 and BL41 B95.8, the amounts of RNA
obtained by the a-BrdU-IPs were too small (50–100 ng) for
microarray analysis using the same experimental setting and
microarray platform. As the control IP is thought to merely repre-
sent total RNA levels in the cell and total RNA has been success-
fully used as control for the Ago2-IP (Weinmann et al., 2009), we
analyzed total RNA instead of the a-BrdU-IP sample for BL41,
BL41 B95.8, and Jijoye. Enrichment of transcripts in the Ago2-
IP was highly concordant for all six human B cell lines irrespec-
tive of whether total RNA or the a-BrdU-IP sample was used
(Pearson’s correlation coefficient between 0.34 and 0.96 for all
combinations, p < 2.2 3 1016). The complete set of data is
provided in Table S1.
To test for overrepresentation of predicted miRNA-binding
sites of cellular miRNAs among the enriched transcripts, we
obtained 44 cellular miRNAs expressed in BL41, BL41 B95.8,
and DG75 from the miRNA expression atlas (Landgraf et al.,
2007) (Table S2A). We used the miRNA target prediction program
PITA (Kertesz et al., 2007) and different DDG cutoff values
ranging from 0 to 10 kCal/mol to test for overrepresentation of
favorable target sites of any of these miRNAs in target 30UTRs
(Figure 1). Overrepresentation was highly significant down to
very low mean enrichments (p < 1058 for a mean enrichment of
1.2-fold). Based on statistical analysis, we identified 2337 tran-
scripts significantly enriched across all six B cell lines (p < 0.05,
one-sided paired t test) with a mean enrichment > 1.2-fold.
Enrichment of their transcripts in the six cell lines is shown
in Figure 2A, and a complete list is provided in Table S2B. For
these genes, predicted binding sites were significantly overrep-
resented within 50UTRs (p = 8.59 3 103), coding sequences
(p = 2.023 1027), and 30UTRs (p = 6.193 1063, Fisher’s exact
test and DDG < 4 kCal/mol, see also Table S3A).Host & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier Inc. 325
Figure 2. Enrichment of miRNA Targets by RISC Immunoprecipita-
tion
Enrichment of cellular (A, n = 2337), KSHV (B, n = 114), and EBV (C, n = 44)
miRNA targets in the Ago2-IPs of the six cell lines under study is shown.
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Targets of viral miRNAs may either be exclusively targeted by
viral miRNAs or also be targeted by cellular miRNAs. In the first
case, their transcripts should only be enriched in the cell lines
expressing the viral miRNAs, but not in the two control cell lines
DG75-eGFP and BL41. For transcripts targeted by both cellular
and viral miRNAs, enrichment in BCBL-1 or Jijoye should be
substantially greater than in the two control cell lines. In order
to exclude false positives, we defined stringent criteria for a tran-326 Cell Host & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier Inscript to be considered a KSHV or EBV miRNA target. Enrich-
ment in either BCBL-1 or Jijoye had to be > 3.0 and enrichment
in both DG75-eGFP and BL41 < 1.2. For targets of cellular miR-
NAs (enriched > 1.2-fold in DG75-eGFP and/or BL41), a > 3-fold
greater enrichment in BCBL-1 or Jijoye than in both DG75-eGFP
and BL41 was required. Enrichment of the 114 KSHV and the 44
EBV putative miRNA targets which fulfilled these criteria are
shown in Figures 2B and 2C, respectively. Interestingly, no tran-
scripts were enriched > 3-fold in either DG75-10/12 or BL41
B95.8 and < 1.2-fold in DG75-eGFP and BL41, which were not
also enriched > 3-fold in BCBL-1 or Jijoye, respectively. This
most likely reflects the reduced levels of viral miRNAs in DG75-
10/12 (see Figures S2A and S2B) and BL41 B95.8.
False-positive viral miRNA targets may result from both cellular
miRNAs and cellular transcripts induced upon infection. On the
one hand, cellular miRNAs induced upon infection may mimic
the effect of the viral miRNAs. While little is known about the effect
of KSHV infection on cellular miRNA expression, EBV infection
has been shown to result in induction of a number of cellular
miRNAs, including hsa-miR-155, hsa-miR-146a, and hsa-miR-
21 (Gatto et al., 2008; Mrazek et al., 2007). Out of 17 confirmed
targets of hsa miR-155 (Gottwein et al., 2007; Skalsky et al.,
2007; Vigorito et al., 2007), we noted six (BACH1, FOS, IKBKE,
RFK, RPS6KA3 [Gottwein et al., 2007] and SPI1 [Vigorito
et al., 2007]) to be enriched between 1.4- and 2.7-fold in Jijoye
(Table S3B). This is consistent with significant repression of
hsa-miR-155 targets upon EBV infection (Gatto et al., 2008).
Still, none of them fulfilled our more stringent criteria. In addition,
none of the 12 targets of hsa-miR-21 identified by Yang et al.
(Yang et al., 2009b) and none of the four targets of hsa-
miR146a (Pauley et al., 2008; Tang et al., 2009) were enriched >
1.5-fold in any of the six cell lines. Thus, we believe that induction
of cellular miRNAs did not significantly corrupt our list of EBV
miRNA targets.
On the other hand, virus infection may result in the induction of
genes that are then targeted by cellular miRNAs. If expression
levels are below the detection limit of the microarrays in unin-
fected B cells, this would present as a selective enrichment of
their transcripts in the Ago2-IP in the infected cells; i.e., they
would be misinterpreted to be viral miRNA targets. Therefore,
we distinguished noninduced targets (KSHV, n = 72; EBV, n = 26;
see Tables S4A and S4B) from targets that showed >1.5-fold
higher expression levels in the BrdU-IPs of BCBL-1 compared
to DG75-eGFP or in total RNA levels of Jijoye when compared to
BL41 (KSHV, n = 42; EBV, n = 18; see Tables S4C and S4D). To
investigate whether these genes are indeed targeted by viral
miRNAs, we studied the overrepresentation of predicted viral
miRNA target sites among both the noninduced and induced
targets using the PITA algorithm. Indeed, predicted target sites
of viral miRNAs were significantly overrepresented in the 30UTRs
and, to a lesser extent, in the 50UTRs among both the induced
and noninduced KSHV and EBV miRNA targets (Tables S3A,
S5A, and S5B). Therefore, we concluded that also the majority
of the genes induced > 1.5-fold in either BCBL-1 or Jijoye are
indeed targets of viral miRNAs.
Validation of Viral miRNA Targets by TaqMan PCR
We representatively validated miRNA targets identified by
RIP-Chip analysis using quantitative TaqMan PCR (qPCR). Wec.
Figure 3. Validation of KSHV and EBV miRNA Targets by qPCR
(A) For each gene, mRNA enrichment (Ago2-IP versus control-IP) normalized
for HPRT expression levels is shown for DG75-eGFP (left), DG75-10/12
(middle), and BCBL-1 (right).
(B) For each gene, mRNA enrichment (Ago2-IP versus control-IP) normalized
for HPRT expression levels is shown for BL41 (left), BL41 B95.8 (middle),
and Jijoye (right). Transcripts with significant enrichment in cells expressing
viral miRNAs are indicated in dark gray and cellular miRNA targets in light
gray. MICA, CCNE1, and H19, which are known to be targeted by cellular
miRNAs, were used as controls. Values represent the mean ± SD of two inde-
pendent experiments performed in duplicate.
Cell Host & Microbe
RIP-Chip Analysis of g-Herpesviral miRNA Targetsrandomly chose 11 KSHV miRNA targets that were also
enriched > 1.5-fold in DG75-10/12. In addition, we chose eight
EBV miRNA targets as well as four well-described targets of
cellular miRNAs. Three of the eight EBV miRNA targets (IPO7,
TRIM32, and FBXO9) were enriched > 1.5-fold in BL41 B95.8.
The rest (n = 5) were not enriched in BL41 B95.8 (enrichment =
0.77–0.96). New RISC-IPs were performed for all six cell lines
using two independent biological replicates. Quantitative PCR
was performed, and expression levels were normalized to hypo-
xanthine-guanine phosphoribosyltransferase (HPRT), a com-
monly used housekeeping gene (Fu et al., 2009), found not
to be enriched in our Ago2-IPs. The noncoding RNA H19
(Weinmann et al., 2009) and cyclin E1 mRNA (CCNE1) served
as quantitative positive controls (Figures 3A and 3B). Enrichment
was significant for 9 of the 11 KSHV miRNA targets in both
DG75-10/12 and BCBL-1. ZNF684 was significantly enriched
only in BCBL-1. All EBV miRNA targets (8/8 = 100%) were signif-
icantly enriched in Jijoye. Significant enrichment in BL41 B95.8
was also observed for IPO7 and TRIM32. Recently, the activating
NK cell ligand MICB was found to be targeted by both ebv-miR-
BART2-5p, kshv-miR-K12-7 (Nachmani et al., 2009) and hcmv-
miR-UL112-1 (Stern-Ginossar et al., 2007). In contrast, MICA,
a closely related NK cell ligand, is predominantly targeted by
cellular miRNAs (Stern-Ginossar et al., 2008). MICB was
enriched significantly stronger in both BL41 B95.8 and Jijoye
than in BL41, consistent with ebv-miR-BART2-5p being one of
the EBV miRNAs still expressed in BL41 B95.8. Enhanced
enrichment of MICB in BCBL-1 was less pronounced but never-
theless detectable. In summary, 18 of 19 (95%) of the viral
miRNA targets we tested by qPCR were confirmed.
Validation of KSHV miRNA Target Candidates
by Dual-Luciferase Assays
In order to experimentally validate viral miRNA targets identified
by RIP-Chip and confirmed by qPCR, we cloned the full-length
30UTRs of 6 of the 11 putative KSHV miRNA targets into
a GATEWAY-compatible derivative of the dual-luciferase vector
pSIcheck. This vector constitutively expresses renilla and firefly
luciferase. Expression of the latter is regulated by the subcloned
30UTR. KSHV miRNAs were expressed by cotransfection of
pcDNAmiR10/12, a vector encoding the ten intronic KSHV miR-
NAs with the reporter constructs, and luciferase assays were
performed 16 hr later. While no effect of KSHV miRNA
expression was detectable for the 30UTR reporter constructs of
NHP2L1 and GEMIN8, significant suppression of firefly lucif-
erase expression was detectable for the other four candidates
in three independent experiments (Figure 4A). The strongest inhi-
bition was exerted on the LRRC8D reporter (50%) construct,
while the effect on CDK5RAP1 was rather small (15%) but
nevertheless reproducible and significant.
LRRC8D Is Regulated by kshv-miR-K12-3 through
a Single Target Site in Its 30UTR
LRRC8D is a leucin-rich type III transmembrane protein thought
to be involved in proliferation and activation of lymphocytes
and macrophages. Modeling of possible hybrids between the
LRRC8D 30UTR and the KSHV-encoded miRNAs suggested
a strong interaction of the 30UTR with kshv-miR-K12-3 (Fig-
ure 4B, Table S6A). To test whether expression of kshv-miR-CellK12-3 alone was responsible for the downregulation of luciferase
activity in the LRRC8D 30UTR reporter construct, we performed
derepression assays by using a 20-O-methyl RNA complemen-
tary to kshv-miR-K12-3. The inhibition of kshv-miR-K12-3
resulted in a concentration-dependent reversion of luciferase
repression, indicating that kshv-miR-K12-3 is selectively capa-
ble of causing the named effect (Figure 4B). To test whether
the predicted binding site on the LRRC8D mRNA is the true
and sole site of interaction with kshv-miR-K12-3, we mutated
the seed region of the putative binding site of kshv-miR-K12-3
by inserting five point mutations according to Ziegelbauer et al.
(Ziegelbauer et al., 2009) (Figure S3B). When the vector carrying
this mutation was cotransfected with the vector expressing the
ten intronic KSHV miRNAs or miR-K12-3 alone, the miRNA effect
was no longer detectable (Figure 4C). These findings demon-
strate that binding of kshv-miR-K12-3 to this single site in the
30UTR of LRRC8D transcripts is necessary and sufficient to exert
the inhibitory effect.
GEMIN8 and NHP2L1 Are Both Regulated through
aKSHVmiRNA-Binding Sitewithin Their Coding Regions
Two KSHV miRNA targets, GEMIN8 and NHP2L1, could not be
validated by 30UTR dual-luciferase assays. Using RNAhybrid,
we tested whether they might be regulated by binding sites
located within their coding sequences or 50UTRs. We identifiedHost & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier Inc. 327
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coding sequence of GEMIN8 and for kshv-miR-K12-3 in the
coding sequence of NHP2L1 (Figure 4D, Tables S6B and S6C).
Reporter constructs were created containing the putative
binding sites (128 nt for GEMIN8 and 146 nt for NHP2L1), and
dual-luciferase assays were performed. In both cases, expres-
sion of the intronic KSHV miRNAs as well as the predicted
individual KSHV miRNAs resulted in a significant repression of
firefly luciferase activity, indicating that these two putative
miRNA-binding sites can indeed be targeted by the respective
KSHV miRNAs. In both cases, binding sites were confirmed by
mutating the seed region of the predicted binding site by intro-
ducing five point mutations (Figure 4D, Figures S3B and S3C).
In addition, significant repression of the luciferase signal was
also observed upon cotransfection with the respective single
KSHV-miRNA-expressing vectors (Figure 4E). To test whether
regulation by KSHV miRNAs had any effect on endogenous
protein levels, we performed quantitative Western blot analysis
using antibodies to GEMIN8 and NHP2L1. While no specific sig-
nal could be obtained for NHP2L1 (data not shown), a 2.5-fold
downregulation of GEMIN8 protein levels was observed for
GEMIN8 in DG75-10/12 compared to DG75-eGFP (Figure 4F).
To test whether isolated expression of kshv-miR-K12-3
or -K12-4 was sufficient to efficiently recruit LRRC8D, NHP2L1,
and GEMIN8 transcripts to Ago2 complexes, we performed
RISC pull-downs in 293 cells expressing doxycyclin (dox)-
inducible kshv-miR-K12-3 (293-miR-K3) or -K12-4 (293-miR-
K4). Consistent with regulation of LRRC8D and NHP2L1 by
kshv-miR-K12-3, qPCR revealed significant enrichment of their
transcripts in the Ago2-IPs of 293-miR-K3 cells following dox
induction, but not in 293-miR-K4 cells (Figure 4G). A weak enrich-
ment of GEMIN8 in dox-induced 293-K12-4 cells was also
detectable, but this did not quite reach significance. Therefore,Figure 4. Validation of KSHV miRNA Targets by Dual-Luciferase Assay
Indicator vectors carrying no additional sequences, or candidate 30UTR sequen
either with empty pcDNA or pcDNA expressing the ten intronic KSHV miRNAs (pcD
miRK4). A vector containing an imperfect match for kshv-miR-K12-4 was used a
renilla luciferase ratios were normalized to the empty pSIcheck2 vector as descr
least three times in triplicate. Values represent the mean ± SD of representative
(A) Six candidate 30UTRs of putative KSHV miRNA targets were tested, four of wh
sion (indicated by asterisks).
(B) The interaction between kshv-miRK12-3 and the 30UTR of LRRC8D was mod
the seed region of kshv-miR-K12-3. Luciferase derepression analysis of LRRC8D
a concentration-dependent derepression indicating that LRRC8D is indeed targe
(C) KSHV miRNA mediated repression of luciferase activity via the LRRC8D 30UTR
lost upon deletion of the putative SEED match for kshv-miR-K12-3.
(D) Putative target sites for KSHV miRNAs located in the coding sequence of GE
luciferase gene. Repression of firefly luciferase activity occurred when KSHV miR
point mutations into the putative SEED-matching regions (bottom).
(E) The sensor vectors carrying putative miRNA target sites from the coding seque
constructs expressing miR-K12-3 or miR-K12-4 resulting in significant repressio
(F) Proteins were labeled by using Alexa488-conjugated secondary antibodies a
employing the AIDA software.
(G) RISC-IPs were performed from 293 cells expressing either kshv-miR-K12-3 (
BCBL-1 served as control. For each gene, mRNA enrichment (qPCR of Ago2-IP v
K3 (left), 293-miR-K4 (middle), and BCBL-1 (right). Enrichment of LRRC8D (p = 0.0
miR-K4 (unpaired t test). Enrichment of GEMIN8 did not quite reach significance
RISC-IPs per condition.
(H) Binding sites for ebv-miR-BART16 and ebv-miR-BART3 in the 30UTR of TOM
vectors carrying the 30UTRs of TOMM22 and IPO7 demonstrated significant repr
were completely reversed when the seed regions of the predicted binding sites
Celladditional miRNAs may be involved in recruiting NHP2L1 and
GEMIN8 to Ago2 complexes.
Finally, we also cloned 30UTRs of three putative EBV miRNA
targets, namely TOMM22 (mitochondrial import receptor subunit
TOM22 homolog), IPO7 (importin 7), and RAB13 (RAB13, mem-
ber RAS oncogene family) into dual-luciferase vectors. Potential
binding sites for EBV miRNAs were predicted using RNAhybrid
(Rehmsmeier et al., 2004). In both cases, the predicted binding
sites (for ebv-miR-BART-16 and ebv-miR-BART-3, respectively)
were validated by luciferase assays by cotransfection of expres-
sion vectors for the respective miRNAs (Figure 4H). Mutagenesis
of the seed regions of the putative binding sites resulted in
complete loss of inhibition. No inhibition of luciferase expression
by EBV miRNAs was detectable for the RAB13 reporter construct
(data not shown).
Characteristics of Cellular and Viral miRNA Targets
It has been a long-standing matter of debate to what extent
miRNAs influence the stability of their targets. Therefore, we
compared transcript half-lives of the cellular miRNA targets
with those of 8300 genes expressed in BL41 taken from our
recently published atlas of transcript half-lives in human B cells
(Friedel et al., 2009). This atlas contained precise transcript
half-lives for 70% of the cellular miRNA targets. With a median
half-life of 4.3 hr, transcript half-lives of the targets of cellular
miRNAs were significantly shorter (Kolmogorov-Smirnov test,
p < 2.2 3 1016) than transcript half-lives of the other genes
expressed in human B cells (median t1/2 = 5.4 hr) (Figure 5A). In
contrast, the median half-life of transcripts identified as viral
miRNA targets was not significantly shorter than the overall
median RNA half-life, indicating that cellular transcripts with short
half-lives are not preferentially targeted by viral miRNAs. Next, we
looked at the correlation of the enrichment in the Ago2-IP in BL41s
ces inserted 30 to the firefly luciferase gene, were cotransfected into HEK293
NAmiRK10/12), kshv-miR-K12-3 (pcDNAmiRK3), or kshv-miR-K12-4 (pcDNA-
s positive control. Dual-luciferase assays were performed 16 hr later. Firefly to
ibed (Gottwein et al., 2007). All dual-luciferase experiments were performed at
experiments.
ich reproducibly caused significant downregulation of firefly luciferase expres-
eled using RNA Hybrid (Rehmsmeier et al., 2004) (top). The black line indicates
30UTR with a sequence-specific AntagomiR (20O-methyl RNA) demonstrated
ted by kshv-miR-K12-3 (bottom).
after coexpression of the ten intronic KSHV miRNAs or miR-K12-3 alone was
MIN8 and NHP2L1 (top) were cloned into pSIcheck2 in the 30UTR of the firefly
NAs were cotransfected. This effect was abolished by the introduction of five
nce of NHP2L1 and GEMIN8 were cotransfected with the respective individual
n of luciferase activity.
nd scanned in the Fluoimager. Reduction of GEMIN8 level was quantified by
293-miR-K3) or -miR-K12-4 (293-miR-K4) following induction with doxycyclin.
ersus control-IP) normalized for HPRT expression levels is shown for 293-miR-
11) and NHP2L1 (p = 0.037) was significant in 293-miR-K3 compared with 293-
(p = 0.062). Means ± SDs represent combined data from three independent
M22 and IPO7, respectively, are shown (top). Luciferase assays with sensor
ession by ebv-miR-BART16 and ebv-miR-BART3, respectively. These effects
(RNAhybrid) were mutated (bottom).
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Figure 5. Effect of miRNAs on Target RNA
Stability
(A) Distribution of the transcript half-life of the
targets of cellular and viral miRNAs was compared
with the transcript half-life of all genes for which
RNA half-lives were available from our recently
published atlas of RNA half-lives in human B cells
(BL41; n = 8,342). The density distribution was
estimated by binning genes according to tran-
script half-lives in intervals of 60 min, counting
the number of genes in each bin, and then normal-
izing the counts such that the area under the curve
is 1. Transcript half-life (x axis) is plotted against
the estimated density (y axis). RNA half-lives of
cellular miRNA targets were significantly lower
(Kolmogorov-Smirnov test, p < 2.2 3 1016) than
for all other cellular transcripts expressed in
human B cells for which RNA half-lives were avail-
able (Friedel et al., 2009). For viral miRNA targets,
no significant difference was observed. Please
note that no viral miRNAs are expressed in BL41
for which the RNA half-lives were obtained.
(B) The extent of recruitment to Ago2 complexes
(enrichment in the Ago2-IP) negatively correlated
with transcript half-life. The distribution of the
half-life of transcripts enriched either R 4-fold,
2- to 4-fold, 1- to 2-fold, and less than 1-fold as
well as of all 8342 cellular transcripts was
compared. A highly significant, negative correla-
tion in between transcript half-life and recruitment
to Ago2 complexes was observed (Spearman
correlation coefficient, 0.13; p value < 1016).
(C) Effect of viral miRNAs on target mRNA levels. The cumulative distribution of alterations in expression levels of cellular, KSHV, and EBV miRNA targets rep-
resented either by the BrdU-IP (for DG75-eGFP versus BCBL-1) or total RNA (for BL41 versus Jijoye) is shown. Genes induced either in BCBL-1 or Jijoye are
represented by a log2 expression ratio > 1.0; genes downregulated in these cells compared to either DG75-eGFP or BL41 by a ratio < 1.0. Genes induced >
1.5-fold in infected cells (right of gray vertical line) are provided in Tables S4C and S4D.
(D) Correlation of enrichment in the Ago2-IP with transcript half-life. The median half-life of transcripts which were enriched more than the indicated value in the
Ago2-RIP-Chip in each of the indicated cell lines (DG75-eGFP, DG75-10/12, and BCBL-1) are shown.
(E) KSHV miRNAs destabilize their targets. RNA half-lives of the KSHV miRNA targets identified by Ago2-RIP-Chip were determined in DG75-eGFP, DG75-10/12,
and BCBL-1 based on nascent / total RNA ratios (n = 3; for details, see Table S7B). Their RNA half-lives were significantly shorter in BCBL-1 (Friedman test,
p = 6.74 3 106) than in both DG75-eGFP and DG75-10/12. This was seen for both the induced and noninduced KSHV miRNA targets but was only significant
for the noninduced (p = 5.253 106), presumably due to the smaller number of induced (n = 35) versus noninduced (n = 70) KSHV miRNA targets for which RNA
half-lives could be determined.
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highly significant negative correlation in between transcript
half-life and recruitment to Ago2 complexes (Spearman correla-
tion coefficient,0.13; p value < 1016). Thus, these data support
previous studies demonstrating that cellular miRNAs have a small
but measurable impact on target RNA stability (Baek et al., 2008;
Selbach et al., 2008). Our data now extend these findings,
showing that the effect on RNA stability correlates with the extent
of target recruitment to Ago2 complexes.
To investigate the effect of viral miRNAs on the transcript
levels of their targets, we first compared expression levels in
DG75-eGFP and BCBL-1 (for KSHV miRNA targets) as well as
in BL41 and Jijoye (for EBV miRNA targets). As a reference, the
changes in expression levels of the 2337 targets of the cellular
miRNAs were used (Figure 5C). For both KSHV and EBV miRNA
targets, the extent and distribution of downregulation was very
similar to that observed for the cellular miRNA targets. Interest-
ingly, we noted that a substantial number of both KSHV
and EBV miRNA targets were expressed at higher levels in
BCBL-1 and Jijoye, respectively. In order to assess whether330 Cell Host & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier InKSHV miRNAs preferentially target transcripts transcribed at
higher rates in infected than in uninfected B cells or whether
they are directly responsible for the increased total RNA levels
by enhancing RNA stability, we determined RNA half-lives for
DG75-eGFP, DG75-10/12, and BCBL-1 by metabolic tagging
of nascent RNA with 4-thiouridine (Friedel et al., 2009). Following
separation of total RNA into nascent and untagged pre-existing
RNA, three biological replicates of all three RNA fractions were
analyzed on Affymetrix Gene ST 1.0 arrays. RNA half-lives of
cellular and viral miRNA targets are provided in Tables S7A
and S7B, respectively. Again, we observed a significant, linear
correlation of recruitment of transcripts to Ago2 complexes
with RNA half-life for all three cell lines (Figure 5D). In DG75-
eGFP and DG75-10/12, half-life distribution and median RNA
half-life of all KSHV miRNA targets were indistinguishable from
other cellular transcripts. In contrast, RNA half-life of KSHV
miRNA targets was significantly shorter in BCBL-1 (t1/2m = 272
min, Friedman test p = 6.74 3 106) than in both DG75-eGFP
(t1/2m = 314 min) and DG75-10/12 (t1/2m = 312 min, Figure 5E).
These data are consistent with the substantially greater meanc.
Figure 6. Transcripts Targeted by miRNAs Are Enriched for
GO-Annotated Functional Classes
Selected GO functional classes of transcripts targeted by cellular (A) or KSHV
(B) miRNAs are shown. The number of transcripts in each class is indicated on
a logarithmic scale, along with the respective p value.
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BCBL-1 (5.5-fold) than of DG75-10/12 (1.5-fold) and DG75-
eGFP (1.2-fold). The half-lives of induced and noninduced
target transcripts were very similar in BCBL-1, indicating that
the increased levels of miRNA target transcripts in BCBL-1 are
not due to enhanced RNA stability but rather an increase in tran-
scriptional rate that is counteracted by the viral miRNAs.
To identify functional categories enriched among both cellular
and viral miRNA targets, we performed a Gene Ontology (GO)
overrepresentation analysis. For targets of cellular miRNAs,
a large number of GO terms were significantly overrepresented,
consistent with cellular miRNAs being involved in a broad spec-
trum of cellular processes (Table S8A). A selected list of these is
shown in Figure 6A. KSHV miRNA targets were preferentially
involved in gene expression and its regulation as well as the spli-
ceosome and protein import into the nucleus (Figure 6B, Table
S8B). No functional categories were overrepresented among
the EBV miRNA targets (Table S8C).
DISCUSSION
Since the identification of virally encoded miRNAs, research on
them has been hampered by the lack of high-confidence targets.
Here we provide a large number of such targets for the two
human g-herpesviruses, KSHV (n = 114) and EBV (n = 44), as
well as cellular miRNAs (n = 2337). Predicted miRNA-binding
sites of cellular miRNAs were highly overrepresented in codingCellsequences (p = 2.02 3 1027) and 30UTRs (p = 6.19 3 1063),
but not in 50UTRs (p = 8.59 3 103). For the viral miRNA targets
we identified, predicted binding sites were predominantly over-
represented in target 30UTRs. We used dual-luciferase assays
to validate six KSHV miRNA targets. For four of them we
observed significant regulation by KSHV miRNAs via their
30UTRs. The two remaining genes (GEMIN8 and NHP2L1) are
regulated by binding sites located within their coding regions.
For GEMIN8 this resulted in a significant reduction of protein
levels.
Despite the much larger number of EBV miRNAs potentially
being responsible for regulation of transcripts selectively
enriched in EBV-infected cells, we could validate TOMM22
and IPO7 as targets of ebv-miR-BART16 and ebv-miR-BART3,
respectively. These two proteins are involved in import of
proteins from the cytosol into the mitochondria (TOMM22) (Saeki
et al., 2000; Yano et al., 2000) and the nucleus (IPO7) (Gorlich
et al., 1997). Antisense knockdown of TOMM22 has been shown
to inhibit the association of the proapoptotic protein BAX with
mitochondria and thus prevent BAX-induced apoptosis (Bellot
et al., 2007). Recently, IPO7 has also been implicated in innate
immunity. Antisense knockdown of IPO7 in macrophages
resulted in reduced production of the proinflammatory cytokine
IL-6 upon LPS challenge (Yang et al., 2009a). This study also
identified FBXO9 as one of four factors required for efficient
production of IL-6 in J774A.1 macrophages. While the function
of FBXO9 is unknown, it is possible to be involved in phosphor-
ylation-dependent ubiquitination of IkB or another important
signaling molecule in the TLR4 pathway or another pathway
that is activated in response to LPS (Yang et al., 2009a). Interest-
ingly, FBXO9 is also in our list of 44 EBV miRNA targets and
was validated by qPCR. Thus, it is intriguing to speculate that
EBV taps the proinflammatory signaling networks by recruitment
of both IPO7 and FBXO9 transcripts to Ago2 complexes. In
summary, this is indicative of EBV miRNAs modulating cellular
trafficking and protein localization to counteract innate immunity
and apoptosis.
In the last few years a number of transcripts have been identi-
fied to be targeted by KSHV and EBV miRNAs. The majority
of KSHV targets were identified based on the finding that
KSHV encodes an ortholog of hsa-miR-155 (kshv-miR-K12-11)
(Gottwein et al., 2007; Skalsky et al., 2007). Gottwein et al.
identified 12 genes to be targeted by both kshv-miR-K12-11
and hsa-miR-155. We found 3 of 12 (25%) of these genes to
be enriched > 2-fold in BCBL-1, but not in DG75-eGFP or
BL41. Of these, SLA (Src-like-adaptor, transcript variant 1) was
the most strongly enriched transcript in BCBL-1 (18.3-fold).
Interestingly, it appeared to be induced > 4-fold in BCBL-1.
An additional 4 of 12 genes (33%) were enriched > 1.5-fold
in BCBL-1. Finally, 5 genes (42%) were enriched > 1.5-fold
stronger in Jijoye or BL41 B95.8 than in both control cell lines,
consistent with their regulation by hsa-miR-155 induced upon
EBV infection (Gatto et al., 2008). In summary, only 1 of the 12
genes (BCLAF1) was not enriched > 1.5-fold in BCBL-1, BL41
B95.8, or Jijoye. We could confirm the differential regulation of
MICA and MICB by both KSHV and EBV as well as cellular
miRNAs (Stern-Ginossar et al., 2007, 2008). During the revision
of this paper, Lei et al. identified kshv-miR-K12-1 to target the
NFkB inhibitor IkBa (NFKBIA) via two binding sites in its 30UTRHost & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier Inc. 331
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pathway is activated, mediating vFLIP inhibition of KSHV lytic
replication (Ye et al., 2008). Our data nicely confirm this regula-
tion by revealing a selective 7.3-fold enrichment of NFKBIA
transcripts in the Ago2-IP of BCBL-1 and to a lesser extent
(2.5-fold) in DG75-10/12. In total, about 60% of the known
KSHV and EBV miRNA targets showed detectable enrichment
in our assay (summarized in Table S3B). The analysis of other
published miRNA targets exemplifies an important aspect of
using RIP-Chip to identify miRNA targets. In contrast to other
methods, this approach is based on positive selection of viral
miRNA targets. In consequence, a lack of enrichment does
not exclude a transcript to be targeted by miRNAs due to
the following reasons: First, some of the transcripts may be
expressed at very low levels and thus be below the detection
limit of the microarrays. Second, an enrichment of as little as
1.2-fold still resulted in a highly significant overrepresentation
of predicted miRNA-binding sites for cellular miRNA targets
(p < 1062). Thus, it may still be consistent with regulation by
a viral miRNA. As we restricted our analysis to strongly enriched
targets (>3-fold), we excluded a large number of viral miRNA
targets. Finally, expression levels of both miRNA and its targets
define whether a miRNA is able to exert a significant effect.
Expression of both is influenced by the cell line and assay
employed; e.g., luciferase assays in HEK293 cells with trans-
fected miRNA expression vectors and reporter constructs.
We observed a significantly overrepresented number of
KSHV and EBV miRNA targets to be expressed at higher levels
in BCBL-1 and Jijoye, respectively, than in the uninfected
cells. By measuring RNA half-lives in DG75-eGFP, DG75-10/
12, and BCBL-1 using a new approach we recently developed
(Do¨lken et al., 2008; Friedel et al., 2009), we found that, despite
higher total RNA levels, the RNA half-life of the induced KSHV
miRNA targets was significantly shorter in BCBL-1 than in
DG75-10/12, DG75-eGFP, and BL41. We conclude that KSHV
miRNAs counteract the increased transcription rates of these
genes in the infected cells and hypothesize that KSHV (and
also EBV) miRNAs preferentially target transcripts induced in
the infected cells.
Another important finding of our study is the linear correlation
between recruitment of transcripts to Ago2-complexes, i.e.,
enrichment in the Ago2-IP, and transcript half-life. This indicates
that this approach allows a quantitative estimate on the true
extent of miRNA mediated regulation. It is tempting to speculate
that more strongly regulated targets are more likely to be biolog-
ically relevant. Therefore, this approach may help to decide
which of the large number of viral miRNA targets to pursue in
further studies. This concept is supported by the strong enrich-
ment we observed for both MICB and NFKBIA, both of which
were not only confirmed by luciferase assay but were also shown
to exert a significant biological effect upon downregulation. In
this respect, we provide a large number of high-confidence viral
miRNA targets. In addition, we provide data for numerous other
transcripts predominantly enriched in either BCBL-1 or Jijoye
that did not quite fulfill our stringent criteria but which most likely
are also targeted by the viral miRNAs. Thus, these data provide
an important basis for further studies aimed to characterize the
viral miRNA targets relevant for the interaction of the virus with
its human host.332 Cell Host & Microbe 7, 324–334, April 22, 2010 ª2010 Elsevier InEXPERIMENTAL PROCEDURES
Generation of Cell Lines Expressing KSHV miRNAs
Human B cells (DG75-eGFP and DG75-10/12) stably expressing either eGFP
or the ten intronic KSHV miRNAs were generated using the ‘‘Virapower’’ lenti-
viral transduction system (Invitrogen) and recombinational cloning following
the manufacturer’s instructions. HEK293 cell lines expressing either doxycy-
clin-inducible kshv-miR-K12-3 or -K12-4 (293-K3 and 293-K4) were generated
using the Flp-In T-REx-293 cell line (Invitrogen) according to the manufac-
turer’s instructions. To induce KSHV miRNA expression, 1 mg/mL doxycycline
was added for 48 hr.
Immunoprecipitation of Human Argonaute 2 Complexes
For the RISC-IPs of human B cells, 5 3 108 cells were taken for each replicate
and washed twice in PBS before lysis in 10 ml lysis buffer containing 25 mM
Tris HCl (pH 7.5), 150 mM KCl, 2 mM EDTA, 0.5% NP-40, 0.5 mM DTT, and
protease inhibitor Complete (Roche). DTT and protease inhibitors were always
prepared freshly and added immediately before use. Lysates were incubated
for 30 min at 4C and cleared by centrifugation at 20,000 g for 30 min at 4C.
Total RNA was prepared from 100 ml of cell lysates using the miRNeasy kit
(QIAGEN) following the manufacturer’s instructions. RISC-IPs were performed
with a few modifications to the previously described protocol (Beitzinger et al.,
2007). In short, 6 mg of purified monoclonal hAgo2 antibody (a-hAgo2; 11A9) or
monoclonal BrdU-antibody (Abcam; used as control) was added to 5 ml of
RPMI medium and incubated with 60 ml of protein G Sepharose beads (GE
Healthcare) in Pierce centrifuge columns (Thermo Scientific) under constant
rotation at 4C overnight. Columns were drained by gravity flow and washed
once with the lysis buffer. Beads were subsequently incubated with 5 ml of
cell lysates for 2.5 hr under constant rotation at 4C. After incubation, the
beads were washed four times with IP wash buffer (300 mM NaCl, 50 mM
Tris HCl [pH 7.5], 5 mM MgCl2, 0.1% NP-40, 1 mM NaF) and once with PBS
to remove residual detergents. RNA was recovered from the beads by adding
700 ml of Qiazol to the columns. After 5 min, the Qiazol lysates were collected
from the columns. This step was repeated once, and the Qiazol lysates were
combined. RNA was prepared using the miRNeasy kit (QIAGEN) according
to the manufacturer’s instructions. RNA samples were eluted in 30 ml H2O.
For RISC-IPs from 293 cells (expressing single KSHV-miRNAs upon 48 hr
induction by doxycyclin), lysates prepared from a single 15 cm dish (80%
confluent) were used, and the IP assay was scaled down by 2-fold. Lysates
from BCBL-1 served as control.
Microarray Sample Labeling, Hybridization, and Preprocessing
For the microarray analysis, 200 ng RNA of each sample was amplified and
labeled using the Affymetrix Whole-Transcript (WT) Sense Target Labeling
Protocol without rRNA reduction. Affymetrix GeneChip Human Gene 1.0 ST
arrays were hybridized, washed, stained, and scanned according to the
protocol described in WT Sense Target Labeling Assay Manual. Microarray
data were assessed for quality and normalized with RMA. All microarray
data are available at Gene Expression Omnibus (GEO) at http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?token=lnelhkuucokacjo&acc=GSE17180.
cDNA Synthesis and Quantitative Real-Time PCR
30-polyadenylation and cDNA synthesis were performed for Ago2-IP, BrdU-IP,
and total RNA samples in a single-step reaction using the miScript Reverse
Transcription kit (QIAGEN). The efficiency of every RISC-IP was monitored
by Light Cycler qRT-PCR for cellular miRNA Let7a using the let7a-specific
primer 50-TGAGGTAGTAGGTTGTATAGTT-30. Microarray data of 24 tran-
scripts were validated by TaqMan PCR using the ABI Prism 7000 sequence
detection system (Applied Biosystems). TaqMan probes were taken from
the Universal Probe Library (Roche), and selection of probe-primer combina-
tions was performed using the Assay Design Centre (Roche, http://www.
universalprobelibrary.com). A list of the utilized PCR primers and probes is
provided in Table S9.
Luciferase Repression and 20O-Methyl-RNA Derepression Assay
To analyze 30UTRs of genes of interest in terms of their ability to interact with
miRNAs, we generated the vector pSIcheck-XE-DEST-sense (reporter
plasmid, see Table S9 for details). For 6 of the 11 KSHV miRNA targetsc.
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30UTRs by PCR using DNA prepared from DG75. To validate putative EBV
miRNA targets, we amplified the full-length 30UTRs of TOMM22, IPO7, and
RAB13 by PCR. TOMM22 and RAB13 were inserted into pMIR-RL (Zhu
et al., 2009) by conventional cloning, and IPO7 was inserted into pSIcheck-
XE-DEST by recombinatorial cloning. For dual-luciferase assays, 10 ng of
the reporter plasmid was cotransfected into HEK293 cells in 24-well plates
with either the respective miRNA-expressing pcDNA vector (200 ng) or the
empty pcDNA vector as negative control. Transfection was carried out using
FuGene 6 (Roche) according to the manufacturer’s instructions. Sixteen hours
after transfection, luciferase activity was measured employing the Dual-Lucif-
erase Reporter Assay (Promega) and the luminometer Fluostar Optima (BMG-
Labtech) as recommended by the manufacturers. For derepression analysis,
HEK293 cells were seeded on 24-well plates as for the luciferase repression
assay and transfected with 100 pmol 20O-methyl-RNA using Lipofectamine
2000 (Invitrogen). Six hours after transfection, the medium was changed and
reporter and miRNA expression plasmids were cotransfected. Sixteen hours
later, luciferase activity was measured.
Overrepresentation of Predicted miRNA-Binding Sites
Cellular miRNAs expressed in all six cell lines were obtained from the miRNA
expression atlas (Landgraf et al., 2007). Their sequences as well as the
sequences of the KSHV and EBV miRNAs were obtained from miRBase v.12
(http://microrna.sanger.ac.uk/sequences/). The 30UTRs, coding sequences,
and 50UTRs for all cellular genes were downloaded from Ensembl (http://
www.ensembl.org/). For all of these, miRNA target sites were predicted using
PITA (Kertesz et al., 2007). Overrepresentation was determined using Fisher’s
exact test.
Metabolic Tagging of Nascent RNA Using 4-Thiouridine
Nascent RNA was tagged in DG75-eGFP, DG75-10/12, and BCBL-1 for 1 hr by
adding 100 mM 4-thiouridine (4sU) to cell culture medium. Biotinylation of 4sU-
tagged RNA and separation of total RNA into nascent and untagged pre-exist-
ing RNA were performed as described (Do¨lken et al., 2008; Friedel et al., 2009).
RNA half-lives were determined based on nascent/total RNA ratios. Median
RNA half-life was normalized to 315 min as obtained for BL41.
Further experimental details are provided in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, Supplemental Experi-
mental Procedures, and nine tables and can be found with this article at
doi:10.1016/j.chom.2010.03.008.
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